Literature DB >> 29783905

Effects of lorazepam on saccadic eye movements: the role of sex, task characteristics and baseline traits.

Ulrich Ettinger1, Inga Meyhöfer1, Mitul A Mehta2, Veena Kumari3, Philip J Corr4, Steven Cr Williams2, Adam M Perkins5.   

Abstract

BACKGROUND: Saccadic eye movements are controlled by a network of parietal, frontal, striatal, cerebellar and brainstem regions. The saccadic peak velocity is an established biomarker of benzodiazepine effects, with benzodiazepines reliably reducing the peak velocity. AIMS: In this study, we aimed to replicate the effects of benzodiazepines on peak velocity and we investigated effects on previously less studied measures of saccades. We also explored the roles of sex, task characteristics and the baseline variables age, intelligence and trait anxiety in these effects.
METHOD: Healthy adults ( N = 34) performed a horizontal step prosaccade task under 1 mg lorazepam, 2 mg lorazepam and placebo in a double-blind, within-subjects design.
RESULTS: We replicated the dose-dependent reduction in peak velocity with lorazepam and showed that this effect is stronger for saccades to targets at smaller eccentricities. We also demonstrated that this effect is independent of sex and other baseline variables. Lorazepam effects were widespread, however, occurring on mean and variability measures of most saccadic variables. Additionally, there were sex-dependent lorazepam effects on spatial consistency of saccades, indicating more adverse effects in females.
CONCLUSIONS: We conclude that saccadic peak velocity is a sensitive and robust biomarker of benzodiazepine effects. However, lorazepam has pronounced effects also on other parameters of horizontal saccades. Sex-dependent drug effects on spatial consistency may reflect cerebellar mechanisms, given the role of the cerebellum in saccadic spatial accuracy.

Entities:  

Keywords:  Lorazepam; anxiety; benzodiazepine; biomarker; oculography; saccadic eye movements; sex differences

Mesh:

Substances:

Year:  2018        PMID: 29783905     DOI: 10.1177/0269881118772450

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  3 in total

1.  Eye tracking: empirical foundations for a minimal reporting guideline.

Authors:  Kenneth Holmqvist; Saga Lee Örbom; Ignace T C Hooge; Diederick C Niehorster; Robert G Alexander; Richard Andersson; Jeroen S Benjamins; Pieter Blignaut; Anne-Marie Brouwer; Lewis L Chuang; Kirsten A Dalrymple; Denis Drieghe; Matt J Dunn; Ulrich Ettinger; Susann Fiedler; Tom Foulsham; Jos N van der Geest; Dan Witzner Hansen; Samuel B Hutton; Enkelejda Kasneci; Alan Kingstone; Paul C Knox; Ellen M Kok; Helena Lee; Joy Yeonjoo Lee; Jukka M Leppänen; Stephen Macknik; Päivi Majaranta; Susana Martinez-Conde; Antje Nuthmann; Marcus Nyström; Jacob L Orquin; Jorge Otero-Millan; Soon Young Park; Stanislav Popelka; Frank Proudlock; Frank Renkewitz; Austin Roorda; Michael Schulte-Mecklenbeck; Bonita Sharif; Frederick Shic; Mark Shovman; Mervyn G Thomas; Ward Venrooij; Raimondas Zemblys; Roy S Hessels
Journal:  Behav Res Methods       Date:  2022-04-06

2.  Impaired Antisaccades in Obsessive-Compulsive Disorder: Evidence From Meta-Analysis and a Large Empirical Study.

Authors:  Katharina Bey; Leonhard Lennertz; Rosa Grützmann; Stephan Heinzel; Christian Kaufmann; Julia Klawohn; Anja Riesel; Inga Meyhöfer; Ulrich Ettinger; Norbert Kathmann; Michael Wagner
Journal:  Front Psychiatry       Date:  2018-06-29       Impact factor: 4.157

3.  Differentiating anxiety from fear: an experimental-pharmacological approach.

Authors:  Julia V Lippold; Ulrich Ettinger; René Hurlemann; Philip J Corr; Martin Reuter; Adam M Perkins
Journal:  Personal Neurosci       Date:  2020-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.